For the estimated 2 million diagnosed patients in the United States who suffer from rheumatoid arthritis (RA), there are multiple prescription therapies that are available for treating the…
Myelodysplastic syndromes (MDS) consists of a group of hematological stem cell disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis…
Is There a Disconnect Between Physician and Payer Perceptions of Therapies Across Key Indications? The treatment of both solid and hematological cancers is associated with a wide range of serious…
Last Updated 23 October 2015 Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—…
The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of…
Myelofibrosis (MF), a rare bone marrow disorder, is one of four chronic myeloproliferative neoplasms (MPN) with no curative therapy except for allogeneic hematopoietic stem cell transplantation. MF…
A Survey of Medical Oncologists and Managed Care Organization Pharmacy and Medical Directors The hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) markets differ with respect to small…
Graft versus host disease (GVHD) is a potentially life-threatening complication of an allogeneic hematopoietic stem cell transplant (HCST). Improvements in allogeneic HSCT strategies have expanded…
TreatmentTrends: Renal Cell Carcinoma 2015 (US) is part of a series of reports that examine current trends in the management of localized to advanced/metastatic renal cell carcinoma (RCC) from the…
Cancer immunotherapy is one of the most exciting fields of research in oncology. Successful drug development in this space offers a highly lucrative opportunity for drug developers. Most excitement…
Securing Market Share and Payer Acceptance in Increasingly Crowded and Segmented Markets in Brazil and Mexico Small molecule therapies offer specific targeting of the aberrant cellular signaling…
A Survey of Oncologists and MCO Pharmacy and Medical Directors Targeted small-molecule agents have emerged as key treatment options for biomarker-defined non-small-cell lung cancer (NSCLC)…
In This Increasingly Crowded Setting, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? Treatment decisions for non-small-cell lung cancer (NSCLC)…
What Attributes Will Distinguish Emerging Therapies, According to Physicians and Payers? Targeted therapies, particularly tyrosine kinase inhibitors (TKIs) that target angiogenesis, dominate the…
What Are Physician and Payer Expectations as New Mechanisms of Action Transform the Market Landscape? Significant opportunity remains for therapies to treat moderate to severe ulcerative colitis (…